Boardroom Alpha
Research library
SPACs · Oct 14, 2026

SPAC Market Update October 14, 2026: Frazier Life Sciences II $75M IPO, COPL / Ignite Proteomics Deal Termination

Frazier Life Sciences Acquisition Corp. II (FLSC) priced a $75M IPO on October 14, 2026, targeting therapeutics and other life sciences assets. Frazier Life Sciences Holdings II LLC sponsors FLSC; separately, FortuneX Acquisition Corp (FXAC) amended its WT…

SPAC IPO Update — October 14, 2026

1 SPAC IPO priced on October 14, 2026, raising $75M; October MTD now stands at 3 IPOs totaling $385M over 14 sessions.

SPAC IPO Count

Monthly IPOs (last 13 months)
Latest: 3•Prior: 5•MoM: -2
14
Oct ’25
10
Nov ’25
22
Dec ’25
24
Jan ’26
27Peak
Feb ’26
11
Mar ’26
16
Apr ’26
20
May ’26
19
Jun ’26
18
Jul ’26
12
Aug ’26
5
Sep ’26
3
Oct ’26
Source: Boardroom Alpha
IPO Activity Snapshot1 SPAC IPO today raising $75M · FLSC ($75M)
Month-to-date: 3 IPOs ($385M) vs. first 14 days of last month 1 ($100M) · 12-mo avg: 16/mo
$ totals include underwriter over-allotment.
Size
$75M
Ticker
Sponsor
Frazier Life Sciences Holdings II LLC

Frazier Life Sciences Acquisition Corp. II aims to raise $75 million through its IPO and will trade on Nasdaq. The SPAC is sponsored by Frazier Life Sciences Holdings II LLC and targets the life sciences sector, focusing on therapeutics addressing unmet medical needs, including oncology, autoimmune diseases, and rare diseases.

Leadership
Albert ChaCEO, Director
Managing Partner of FLS; previously Managing Partner at Vivo Capital LLC; serves as chairman of Ascendis Pharma A/S.
Benjamin L. PalleikoDirector
Led KalVista Pharmaceuticals through a $1.9 billion acquisition by Chiesi Group; former SVP & CFO at Ore Pharmaceutical Holdings.
Fran AdamsCFO
CFO of Research Alliance Corp IV and III; Partner at van den Boom and Associates with over 20 years in accounting and finance.
Richard Scott StruthersDirector
Co-founder and former CEO of Crinetics Pharmaceuticals; founder and chair of Radionetics Oncology, Inc.
William FaireyDirector
Former EVP and Chief Commercial Officer of MyoKardia; serves on the boards of Mirum Pharmaceuticals, Ascendis Pharma, and Rein Therapeutics.
New SPAC IPOs
Date Ticker Issuer IPO Size Trust Funding
Oct 14 FLSC Frazier Life Sciences Acquisition Corp. II $75M 100.0%
Oct 06 PAXG PINE TREE ACQUISITION CORP $100M 100.0%
Source: Boardroom Alpha

Daily SPAC Update — October 14, 2026

SPAC VOTE RESULTS
IX ACQUISITION CORP (IXAQF) * Extend to October 12, 2027435,000 redeemed
BLACK HAWK ACQUISITION CORP (BKHA) * Deal Approved with Vesicor Therapeutics, Inc.2,089,162 redeemed · $25,153,510 removed · trust $12.04

SPAC DEALS ANNOUNCED
October 13 | Horizon Space Acquisition I Corp (HSPOF) + ArcheNova Biotech CorpArcheNova Biotech Corp is a clinical-stage biopharmaceutical company that focuses on the research, development, and commercialization of drugs derived from MSC-derived extracellular vesicles and exosomes. It is advancing five product candidates across various therapeutic areas, including dermatology, orthopedics, ophthalmology, neurology, and cardiology. Its lead candidate for psoriasis has completed a Phase I study and is preparing for a Phase II trial.
October 9 | Quantumsphere Acquisition Corp (QUMS) + Fortune Favor Technology IncFortune Favor Technology Inc. provides technology consulting services and solutions for medical cold-chain transportation through its subsidiaries. It offers design, sourcing, supply chain, and application support for temperature-sensitive products. The company serves medical terminals, distributors, and operators with both standard and customized solutions.
October 9 | Gigcapital8 Corp (GIW) + Quantisimo CorpQuantisimo Corp is developing a sovereign quantum vertical platform focused on integrating various quantum technologies, including cryptographic roots of trust, post-quantum security, and quantum networking. It plans to build an initial portfolio that includes interests in Miraex SA, SEALCOIN AG, WeCan Group SA, and WISeSat.Space Holdings Corp. The company aims to expand its quantum capabilities through technology development, strategic investments, and acquisitions.

SPAC EXTENSIONS
QUETTA ACQUISITION CORP (QETA) * Extension FilingStockholders approved extending the SPAC deadline to 2027 for completing a business combination, with up to twelve one-month extensions funded by deposits. Redeemed 1,550,843 shares for about $18.4 million, leaving 149,860 shares outstanding.
QUETTA ACQUISITION CORP (QETA) * Extension FilingQuetta Acquisition deposits $5,000 extension payment to extend SPAC business‑combination deadline by one month to Nov 10, 2026.
EUREKA ACQUISITION CORP (EURK) * Extension FilingMarine Thinking funded Eureka’s one-month extension for the SPAC via an unsecured Extension Promissory Note convertible into private units.
RISING DRAGON ACQUISITION CORP (RDAC) * Extension FilingRising Dragon issued two unsecured notes of $55,637.41 to SZG Limited to extend the merger deadline to Oct 15, 2026; notes are non-interest bearing and may be converted into private units at $10 per unit.

SPAC DEAL TERMINATIONS (Last 10 Days)
2026-10-09: COPL + Ignite Proteomics Holdings,

OTHER SPAC NEWS
CALISA ACQUISITION CORP (ALIS) * Forward Purchase AgreementAmended prepaid forward purchase agreement to fund the business combination; up to 3,000,000 forward shares at approximately $10.31 per share.
COPLEY ACQUISITION CORP (COPL) * Deal TerminationCopley Acquisition Corp and Ignite Proteomics terminate their Business Combination Agreement; Copley will pursue a new deal, with a November 2, 2026 deadline.
FORTUNEX ACQUISITION CORP (FXAC) * Merger Agreement AmendmentFortuneX, WT Realty, and Merger Sub amended the Business Combination Agreement to reduce Aggregate Merger Consideration to 52.5 million shares (implied $525M at $10/share); the total remains a fixed number of shares with no post-signing adjustments.
HORIZON SPACE ACQUISITION I CORP (HSPOF) * Merger Agreement
PIONEER ACQUISITION I CORP (PACH) * Merger Agreement
QUANTUMSPHERE ACQUISITION CORP (QUMS) * Merger Agreement
SIZZLE ACQUISITION CORP II (SZZL) * Investor Deck

SPAC LISTING RULE NOTICES
QUETTA ACQUISITION CORP (QETA) * Listing Rule NoticeNasdaq delists Quetta Acquisition for failure to complete a business combination; stock to trade on OTC Pink; no appeal.

SPAC Executive & Director Moves — October 14, 2026

SPAC Executive & Director Moves
Company Ticker Moves
M EVO GLOBAL ACQUISITION CORP II MEVO
  • Richard Majlinder was appointed as a director of M Evo Global Acquisition Corp II effective October 6, 2026, filling a board vacancy. He will serve as a Class III director and on the Audit and Compensation Committees; no compensation terms are disclosed, and his letter and indemnity agreements provide substantially the same rights and obligations as certain other directors.  (view source)
Source: SEC EDGAR filings via Boardroom Alpha

SPAC Movers — October 14, 2026

YESTERDAY’S TOP SPAC GAINERS
Company Ticker Change Price Stage
FUTURE VISION II ACQUISITION CORP FVN 6.6% $ 8.45 Announced
CHURCHILL CAPITAL CORP XI CCXI 3.5% $ 11.16 Announced
SILVERBOX CORP IV SBXD 2.6% $ 11.39 Announced
CAYSON ACQUISITION CORP CAPN 2.5% $ 11.55 Pre-Deal
RESEARCH ALLIANCE CORP IV RACD 2.5% $ 11.99 Pre-Deal
YESTERDAY’S TOP SPAC LOSERS
Company Ticker Change Price Stage
CALISA ACQUISITION CORP ALIS -23.3% $ 7.90 Announced
STARRY SEA ACQUISITION CORP SSEA -5.9% $ 10.34 Announced
BLACK HAWK ACQUISITION CORP BKHA -4.0% $ 12.48 Announced
RISING DRAGON ACQUISITION CORP RDAC -2.7% $ 5.43 Announced
QUETTA ACQUISITION CORP QETA -2.6% $ 11.30 Announced
Source: Boardroom Alpha market data

Frequently Asked Questions

  • How many SPAC IPOs priced in October 2026 through October 14?
    3 SPAC IPOs priced for $385M, including over-allotment, through the first 14 sessions of October 2026, versus 1 IPO for $100M over the same span in September 2026.
  • Who sponsors FLSC and what does it target?
    Frazier Life Sciences Holdings II LLC sponsors Frazier Life Sciences Acquisition Corp. II (FLSC). The SPAC targets life sciences opportunities, including therapeutics for unmet medical needs.
  • How much was redeemed on BKHA‘s Vesicor approval vote?
    Black Hawk Acquisition Corp (BKHA) had 2,089,162 shares redeemed, removing $25M from trust at $12.04 per share, after shareholders approved the Vesicor Therapeutics, Inc. combination.
  • What did IX Acquisition Corp shareholders approve?
    IX Acquisition Corp (IXAQF) received approval to extend its deadline to October 12, 2027 after 435,000 shares were redeemed; no trust-dollar removal figure was provided.
  • What changed in the FXAC-WT Realty merger agreement?
    FortuneX Acquisition Corp (FXAC) amended its WT Realty merger agreement to reduce consideration and keep the consideration as a fixed share amount with no post-signing adjustments.


Get it in your inbox

The Daily SPAC Update in your inbox

Every IPO, vote, and DeSPAC close — analyzed daily for finance professionals.

ShareXLinkedIn

Published Oct 14, 2026

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer